The Real GLP-1 Debate: Is Obesity A ‘Disease?’

 
• By Michael McCaughan

The US Medicare agency’s proposal to cover weight loss drugs hinges on defining obesity as a disease. While the characterization matches the growing medical consensus, the incoming Trump Administration may not agree.

Will the Trump Administration rescind the Medicare anti-obesity medication coverage proposed rule? Past comments suggest the answer is not clear cut. (Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Medicare

More from Market Access